The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Stacy Ku - TD Cowen - Analyst
: Hey, thanks so much for taking our questions and congratulations on a great quarter. First question is on Qelbree. Can you just talk about what
kind of net pricing dynamics we saw in the quarter and maybe how we should think about the quarterly, let's say, net pricing for Qelbree moving
forward? In addition, maybe provide an update on the Qelbree launch progress in the adult segment and maybe that understandable focus on
Question: Stacy Ku - TD Cowen - Analyst
: Wonderful. And just to confirm, those 200 patients that you're saying, slightly more than 200 that are on ONAPGO, they're getting -- you guys are
getting reimbursement for that? Or is there more of a, let's say, specialty pharmacy bridging program that's ongoing?
Question: Stacy Ku - TD Cowen - Analyst
: Okay, understood.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 05, 2025 / 8:30PM, SUPN.OQ - Q2 2025 Supernus Pharmaceuticals Inc Earnings Call
Question: Unidentified Participant - - Analyst
: Hey, congrats on the quarter. This is John on for Andrew. Thanks for taking my question. So we saw ZURZUVAE Q2 sales accelerate meaningfully
Question: Unidentified Participant - - Analyst
: Great, thank you so much.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 05, 2025 / 8:30PM, SUPN.OQ - Q2 2025 Supernus Pharmaceuticals Inc Earnings Call
Question: Unidentified Participant - - Analyst
: Hi, this is Jack on for Annabel. Thanks for taking our questions. So on the topic of the OB/GYNs, you've noted that this is the best area for expansion
for ZURZUVAE. But your real point of leverage historically has been psychiatry. So how do you plan on balancing these two? What type of investment
do you need to make to kind of reach these prescribers?
And does Biogen need to kind of get on board with that decision?
Question: Unidentified Participant - - Analyst
: Thanks. And then [Tim], one more from us. Just wanted to understand the dosing dynamics for Qelbree in adults a little bit better. Is there still the
same level of combination usage with stimulants? And if so, why is that so persistent? I would think that would kind of defeat the purpose and
advantage of Qelbree being a nonstimulant in that case.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 05, 2025 / 8:30PM, SUPN.OQ - Q2 2025 Supernus Pharmaceuticals Inc Earnings Call
Question: Unidentified Participant - - Analyst
: Very helpful. Thanks for the explanation.
Question: Unidentified Participant - - Analyst
: Hi, thanks for taking our question. This is Alex on for David. Can you please talk to your commercial infrastructure to support ZURZUVAE in postpartum
depression, particularly in terms of headcount and how many practitioners it's targeting? And anything you plan to do differently than Sage? Thank
you.
Question: Unidentified Participant - - Analyst
: Okay. Thank you.
| 
